Articles from HighLife

Paris, France, September 22 – HighLife SAS, a MedTech company focused on transcatheter solutions for structural heart disease, today announced the successful completion of a $90+ Million (€80 Million) financing round. The fundraise was co-led by Andera Partners, Sofinnova Partners, Supernova Invest and Mérieux Equity Partners. Other new investors also joined the round, including the European Investment Bank, BNP Paribas Développement, Capricorn Partners, Critical Path Ventures, Pro Benefis Familiae, SPRIM Global Investments Ltd. and a global strategic alongside existing investors USVP, Sectoral and VI Partners, who participated in the round. The capital will accelerate HighLife's commercial expansion across Europe and advance its US clinical development program.

Paris, France - August 27, 2026 – HighLife SAS, a medical technology company focused on the development of a unique transcatheter mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, today announced CE Mark approval for the HighLife Clarity Mitral Heart Valve for use with the HighLife Transcatheter Mitral Valve Replacement (TMVR) System. 

HighLife Receives CE Mark Approval for its TMVR Solution

HighLife Receives IDE Approval to Initiate US Pivotal Clinical Study for treatment of Mitral Regurgitation

HighLife SAS, a medtech company focused on the development of a novel Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced today the introduction of a new valve size in its clinical trials, the Large Annulus Valve (LAV), designed for patients with larger anatomies.